Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is an early-stage biopharmaceutical company that has a positive outlook as it has demonstrated positive interim results in its ongoing Phase 2 trials for Alzheimer's disease, with a high potential in addressing the large market for the disease and achieving significant milestones in mid-2026. Its latest financial results show a slight increase in revenue and a decreasing net loss. The company is also making progress in its other investigational drug candidates and has achieved over 70% patient enrollment in its Phase 2 CALMA trial of IGC-AD1. As a result, the company's current valuation is attractive, with a projected significant upside potential based on a NPV analysis.

Bears say

IGC Pharma is a Maryland-based clinical-stage pharmaceutical company with a negative outlook, as their 5 drug candidates for Alzheimer's disease have only shown potential in Alzheimer's cell lines and their fiscal year change from March to December may introduce accounting discrepancies. Additionally, the Alzheimer's market is highly competitive with no known cure or means of prevention, and the company faces numerous risks to achieving their share price target, including balance sheet and liquidity risks, failure of product candidates in clinical trials, and changing macroeconomic factors.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.